Sign Up Today and Learn More About Sionna Therapeutics Stock
Invest in or calculate the value of your shares in Sionna Therapeutics or other pre-IPO companies through EquityZen's platform.
Sionna Therapeutics Stock (SITH)
Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).
About Sionna Therapeutics Stock
Founded
2018
Headquarters
Natick, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Sionna Therapeutics Press Mentions
Stay in the know about the latest news on Sionna Therapeutics
Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
biospace • Mar 20, 2025
Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
globenewswire • Mar 20, 2025
TD Cowen Starts Sionna Therapeutics (SION) at Buy
streetinsider • Mar 05, 2025
Eight respiratory disease companies advancing innovative therapies in 2025
labiotech • Mar 01, 2025
Sionna Therapeutics’ NBD1 stabilizers hold potential for cystic fibrosis
thepharmaletter • Mar 01, 2025
Sionna Therapeutics Management
Leadership team at Sionna Therapeutics
Board Member
Bruce Booth
Board Member
Edd Fleming
Join now and verify your accreditation status to gain access to:
- Sionna Therapeutics Current Valuation
- Sionna Therapeutics Stock Price
- Sionna Therapeutics Management
- Available deals in Sionna Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Sionna Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Sionna Therapeutics Revenue and Financials
- Sionna Therapeutics Highlights
- Sionna Therapeutics Business Model
- Sionna Therapeutics Risk Factors
- Sionna Therapeutics Research Report from SACRA Research
Trading Sionna Therapeutics Stock
How to invest in Sionna Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Sionna Therapeutics through EquityZen funds. These investments are made available by existing Sionna Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Sionna Therapeutics stock?
Shareholders can sell their Sionna Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
